Recent studies have demonstrated that chronic obstructive pulmonary disease (COPD) is associated with cardiovascular disease (CVD). However, the association between COPD and coronary microcirculatory dysfunction is unknown. We sought to assess whether myocardial perfusion reserve (MPR) is impaired in patients with COPD, even in the absence of regional myocardial ischaemia or infarction, by using quantitative myocardial perfusion cardiovascular magnetic resonance (CMR).
Introduction
Chronic obstructive pulmonary disease (COPD), characterized by chronic airflow limitation, is the fourth largest cause of death worldwide. 1 In the Lung Health Study, cardiovascular diseases (CVDs)
were the leading cause of hospitalization, accounting for nearly 50% of all hospital admissions, and the second leading cause of mortality, accounting for a quarter of all deaths in mild-to-moderate COPD. 2 Smoking is an established risk factor for CVD, but the effects of smoking seem to be insufficient to explain excess cardiovascular risk in COPD. Although recent studies have demonstrated low-grade systemic inflammation as a possible common pathway of disease progression between COPD and atherosclerosis, 3, 4 it remains to be shown whether the association is coincidental or is related to the systemic inflammation of COPD. Coronary microcirculatory dysfunction is present in the earliest stages of atherogenesis and precedes significant angiographic stenosis, 5, 6 identifiable perfusion deficits, and wall motion abnormalities with traditional imaging methods. 7 -9 In a recent study evaluating coronary circulatory function, by using positron emission tomography, an abnormal myocardial perfusion reserve (MPR) has been a powerful, independent predictor of cardiac mortality in patients with known or suspected coronary artery disease (CAD), and the MPR value ,1.5 was associated with a 16-fold increased risk for cardiac death, compared with the MPR value .2.0. 10 However, no data are currently available regarding the relationship between COPD and coronary circulatory dysfunction. Stress-rest perfusion cardiovascular magnetic resonance (CMR) has emerged as a non-invasive method that can provide a more objective evaluation of myocardial ischaemia and microvascular dysfunction 11 -15 by performing quantitative evaluation of myocardial blood flow (MBF), and by analysing myocardial and blood signal intensity time curves. Accordingly, the purpose of our study was to determine whether the presence of COPD is associated with alteration of MPR assessed non-invasively with myocardial perfusion CMR.
Methods

Study subjects
A total of 60 subjects with a normal CMR study (normal LV and RV wall motion, no regional myocardial ischaemia, and no myocardial scar) were enrolled between 1 January 2006 and 30 August 2010: 20 individuals with mild-to-moderate COPD; 20 age-matched control smokers, and 20 agematched control-never smokers without airflow obstruction. An ejection fraction of 50% or higher with normal movement and thickening of the LV and RV wall segments was considered normal. The presence or absence of regional myocardial ischaemia on stress perfusion CMR and myocardial scar on late gadolinium enhanced CMR were visually assessed by consensus of two observers. All subjects had no (i) clinical sign of CAD (e.g. chest pain or electrocardiogram (ECG) abnormalities), (ii) diabetes mellitus (defined as fasting glucose .126 mg/dL, haemoglobin A1c .6.5, self-reported history of diabetes, or taking diabetes medications), and (iii) more than one traditional CAD risk factor except for cigarette smoking. In this study, individuals with cardiomyopathies, myocarditis, valvular heart disease, congenital heart disease, percutaneous intervention and coronary bypass grafting, as well as general contraindications to CMR such as claustrophobia, pacemakers, or implantable defibrillator devices were not included. Subjects with COPD receiving long-term oxygen therapy were excluded. Control smokers were current smokers with a .10 pack-year smoking history, while control-never smokers were never smokers. The absence of lung disease in control subjects was by clinical evaluation, chest radiograph, and spirometry. All examinations were approved by our institution's review board on medical ethics and clinical investigation.
Spirometry, clinical measurement, and biochemical measurement
Spirometry was performed with equipment that met the American Thoracic Society performance criteria. 16 To adjust for height, age, sex, and race, we used published prediction equations for forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC). 17 We used a FEV1-FVC ratio of,0.70 to define airflow limitation. 18 All subjects underwent physical examinations, anthropometric measurements, risk factor evaluation, and biochemical screening. The 10-year Framingham risk score (FRS) was also calculated for all subjects. Body mass index (BMI) was calculated from measurements of height and weight. Obesity was considered present if the calculated BMI .25 kg/m 2 . Hypercholesterolaemia was diagnosed as total cholesterol .240 mg/dL, or self-reported history of hypercholesterolaemia. Blood pressure was measured using a mercury sphygmomanometer in a quiet room after .10-min rest. Hypertension was defined as systolic blood pressure .140 mmHg, diastolic blood pressure .90 mmHg, self-reported history of hypertension, or current use of antihypertensive medications. Smoking status was assessed with a self-administered questionnaire. Routine blood samples were obtained after 8 h of fasting and blood count, and chemistry analyses were performed.
CMR image acquisitions
Initial scout images were obtained in three orthogonal directions to determine the position of the heart and diaphragm. Trans-axial cine CMR images and vertical long-axis cine CMR images of the left ventricle (LV) were also acquired. First-pass contrast-enhanced myocardial perfusion CMR images were obtained during ATP stress and in the resting state using a 1.5-T MR imager (Achieva, Philips Medical Systems, Best, the Netherlands) with five-channel cardiac coils around the chest. After initial survey images were acquired, a reference scan was performed (repetition time ¼ 8.0 ms, echo time ¼ 0.56 ms, field of view ¼ 53 × 53 cm, acquisition matrix ¼ 48 × 35) to evaluate the individual coil sensitivities for subsequent SENSE imaging. First-pass myocardial perfusion CMR images were obtained in short-axis imaging planes of the LV with a saturation-recovery balanced turbo field-echo sequence (a simple 908 saturation pulse, repetition time of 3.0 ms, echo time of 1.2 ms, flip angle of 458, field of view of 36 × 32 cm, section thickness of 8 mm, acquisition matrix of 128 × 128, SENSE factor of 2, time between saturation preparation pulse and centre of k-space acquisition of 200 ms, and duration of image data acquisition of 210 ms). The k-space filling was performed by using a sequential linear order. The inhomogeneous surface coil intensity profile was corrected by using the SENSE reference scan data. 19 Dynamic CMR acquisition in four short-axis imaging planes of the LV was repeated continuously every two cardiac cycles, i.e. the temporal resolution is over two RR intervals. No partial Fourier was used. For both stress and rest perfusion CMR, gadolinium contrast medium (gadopentetate dimeglumine, Magnevist, Schering, Berlin, Germany) was injected into the right antecubital vein at a dose of 0.05 mmol/kg and a flow rate of 4 mL/s, followed by a 20-mL saline flush. The dual bolus method was employed by injecting a bolus of contrast medium diluted to 10% with saline (0.005 mmol/kg) prior to stress and rest perfusion CMR that does not cause saturation of the blood signal 20 in order to correct for the non-linear relationship between the blood concentration of MR contrast medium and MR signal intensity during the first pass. Dynamic CMR images were acquired for 1 min. The subjects were instructed to begin holding their breath at the start of the image acquisition and to maintain the breath hold as long as possible. Pharmacological stress was achieved by injecting ATP (160 mg/kg/min) in the left antecubital vein for 4 min. Symptoms, blood pressure, heart rate, and ECG were monitored while the subjects were in the magnet, and any serious adverse reaction caused by the pharmacological stress was recorded throughout CMR examination. Three minutes after starting ATP administration, the acquisition of stress myocardial perfusion CMR images were initiated and ATP was continuously injected during the acquisition of stress perfusion CMR. Rest myocardial perfusion Impaired MPR in patients with COPD CMR was acquired at least 10 min after finishing stress myocardial perfusion CMR.
CMR image analysis
Stress-rest first-pass myocardial perfusion CMR images and cine CMR images were analysed using an image analysis workstation (Virtual Place, Aze, Tokyo, Japan). Epicardial and endocardial contours of the LV myocardium were manually determined to obtain myocardial time -intensity curves, and the region of interest (ROI) was placed in the LV chamber to generate the blood time -intensity curve. On a representative image from the dynamic series of myocardial perfusion CMR, the observer manually traced the epicardial and endocardial contours of the LV myocardium in four slices and placed a circular ROI in the LV blood pool depicted on the most basal slice. All contours were then automatically copied to the other dynamic images of each slice, and their positions and shape were reviewed and manually adjusted to correct for respiratory motion during data acquisition. The LV myocardium was divided into 16 segments, consisting of six basal segments, six midventricular segments, and four apical segments based on an AHA 17 segment model excluding the apical segment. Signal saturation of the LV blood signal was corrected using a dual bolus method. The saturation correction method for the LV blood signal was previously reported in detail. 21 In brief, the saturation correction method is composed of the following three steps: (i) the curve that represents the relationship between observed MR blood signal intensity and the Gd-DTPA concentration was obtained by the blood phantom study beforehand. On this curve, the theoretical linear curve of the blood signal intensity vs. Gd-DTPA concentration without saturation effects was determined by linearly extrapolating the low-concentration data points. The ratio of those two curves was defined as the saturation ratio.
(ii) In each pre-and main-bolus scan, which was separately performed, the peak LV blood signal intensity was automatically obtained after the baseline LV signal was manually defined. From those scans, the saturation ratio at the peak was automatically determined. (iii) The blood time -signal intensity curve with saturation effect after the injection of non-diluted gadopentetate dimeglumine (Gd-DTPA) was converted into the saturation-corrected blood time -signal intensity curve by using the look-up table. After this correction process, the MR blood signal intensity vs. time curve in the LV chamber was proportional to the gadolinium concentration during the first pass and temporally aligned with the myocardial signal -intensity curve. Patlak plot analysis was performed using a blood time -intensity curve as an input function and a regional myocardial time -intensity curve as an output function. 21 The range of the least square fitting for Patlak plot analysis was automatically optimized using an algorithm that maximizes the correlation coefficient of the smallest square fitting. On the Patlak plot, starting from the point corresponding to the peak value of the LV blood pool, 3 -6 points were fitted and the one with the highest correlation coefficient was taken as the end point of the fit. Then moving backwards from the point corresponding to the peak value of the LV blood pool, the one with the highest correlation coefficient was taken as the beginning point of the fit. Thus, the range of the least square fitting for Patlak plot analysis was automatically defined. After calculating perfusion parameter K 1 in 16 myocardial segments, MBF was calculated as K 1 divided by the extraction fraction of Gd-DTPA, using the extraction fraction values in the previous studies. 19 Because the rest MBF is closely related to the rate -pressure product, the rest MBF value was corrected for the respective rate -pressure product, that is, the absolute MBF was divided by the rate -pressure product, and the resulting quotient was divided by 10 000. MPR was determined as stress MBF divided by rest MBF corrected for the rate -pressure product. On cine CMR images, the LV contours were drawn manually, and LV end-diastolic volume, end-systolic volume, stroke volume, ejection fraction, and end-diastolic LV mass were calculated. However, RV mass could not assessed, because there were no patients with thicker RV walls. Values were indexed by body surface area. 
Statistical analysis
Results
Baseline clinical and biochemical characteristics of the groups are summarized in Table 1 . The mean age of all subjects was 67 years, ranging from 47 to 81 years of age. Control smokers had pack-year histories similar to those of COPD subjects. There were no significant differences in the incidence of hypertension, hypercholesterolaemia, and BMI. The mean FRS was statistically significantly higher in control than in control-never smokers (P , 0.05 after Bonferroni correction), while the FRS was higher in subjects with COPD than with control-never smokers, but the difference was not significant. COPD subjects had significantly lower FEV1, percent predicted FEV1, and FEV1-FVC ratio than control (P , 0.05 after Bonferroni correction, respectively) and control-never smokers (P , 0.05 after Bonferroni correction, respectively), whereas control and control-never smokers had similar pulmonary function test results. Subjects with COPD showed significantly higher CRP, compared with control-never smokers (P , 0.05 after Bonferroni correction). The CRP level was higher in control than in control-never smokers, but the difference was not significant. There were no significant differences in at-rest and stress heart rates, systolic blood pressure and rate-pressure product between the control-never smokers, control smokers, and COPD patients ( Table 2) . CMR parameters are presented in Table 3 . There were no significant differences in RV and LV end-diastolic volume indices, end-systolic volume indices, stroke volumes and ejection fractions, and LV mass index among the three groups. No significant differences were found in the rest MBF between the groups (1.36 + 0.67 vs. 1.48 + 0.81 vs. 1.06 + 0.69 mL/min/g, P ¼ 0.64). However, COPD subjects had lower stress MBF compared with control and control-never smokers, and the statistical difference was shown between COPD subjects and control-never smokers (2.25 + 0.93, 3.09 + 1.37, and 3.17 + 1.33 mL/min/g, P , 0.05 after Bonferroni correction, respectively). Subsequently, the mean MPR was significantly lower in COPD subjects than in control and control-never smokers (1.76 + 0.58, 2.57 + 1.30, and 3.56 + 1.27, P , 0.05 after Bonferroni correction, respectively) ( Figure 1 ). Variables given are mean + SD. No significant differences in the at-rest and stress heart rates, systolic blood pressure, or rate -pressure product between the control-never smokers, control smokers, and patients with COPD were observed. COPD, chronic obstructive pulmonary disease. 
Discussion
Premature, accelerated coronary atherosclerosis is an established complication of COPD. In the present study, we found a novel finding, namely that COPD and airflow limitation, rather than smoking status, are strongly associated with impaired MPR. These findings may suggest coronary microcirculatory dysfunction, which plays a pivotal role in the development, progression, and clinical manifestations of CAD. An abnormal coronary vasomotor response is also a marker for subclinical disease, an independent predictor of adverse cardiovascular events, and a potential target for medical interventions. 22 -24 Despite the importance of this measure of dynamic vasomotor function, previous reports were based on studies in peripheral vessels, whose function correlates only modestly with that of the coronary arteries. 25, 26 Although the non-invasive assessment of brachial artery endothelial function has been used as a surrogate measure of coronary vascular function, data from flow-mediated dilatation in the brachial artery cannot automatically be extrapolated to the coronary circulation 27 control-never smokers. The mean MPR was significantly lower in COPD subjects than in control and control-never smokers.
In the present study, lower FEV1 showed significant linear positive associations with reduced MPR, independent of smoking and other risk factors. These observations in our study support the previous work by Barr et al., 28 who reported a relationship between flowmediated vasodilation and FEV1 and emphysema severity in COPD patients. Several epidemiological investigations have shown a link between FEV1 and cardiovascular mortality. 29 -31 Thus, this relationship may be mediated by the alteration of MPR. Interestingly, we demonstrated a significant inverse association between CRP and MPR. Moreover, it should be noted that the CRP level was a powerful, independent predictor for reduced MPR, even after taking classical coronary risk factors and other potential confounders into consideration. CRP has emerged as one of the most important predictors of myocardial infarction, stroke, and vascular death in several settings. 32 CRP, at concentrations known to predict vascular disease, directly stimulates diverse early atherosclerotic processes, including endothelial cell adhesion molecules 33 and macrophage low-density lipoprotein uptake, 34 and this may also affect the capillary permeability, which is closely related to the extraction fraction for permeability-limited tracers, such as gadolinium contrast. In addition, this observation in our study supports previous works by Verma et al., 35, 36 who reported a direct effect of CRP on endothelial function. Several clinical reports demonstrated the relationship between CRP and impaired MPR in patients with systemic inflammatory, autoimmune disease, such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). 37, 38 Recently, Thomsen et al. 39 have reported that elevated level of CRP is associated with an increased risk of ischaemic heart disease in COPD patients. These findings may suggest that the influence of systemic inflammation in conditions such as COPD (but also including other chronic inflammatory diseases such as RA and SLE) may exceed that of traditional risk factors in affecting MPR. The possibility that impaired MPR is the cause of systemic inflammation and COPD should be discussed, because this study is observational. Decreased MPR causes the inability to increase blood to the myocardium on exercise, 40 which will likely develop subendocardial dysfunction, 41 and subsequently contribute to inflammation and exercise intolerance associated with COPD. In the present study, current smokers had statistically significantly lower MPR than non-smokers even after multivariable analysis. Although pack-years of smoking showed moderate univariate associations with reduced MPR, these relationships were no longer significant with multivariable analysis. We can therefore assume that factors other than smoking exert greater influences on decreased MPR. Smokers had higher CRP compared with nonsmokers, although the significance of CRP in smokers was lost after Bonferroni correction for multiple variable testing. Agusti et al. 42 have demonstrated that CRP is persistently raised in a large proportion of smokers without COPD. The reduced MPR in smokers may be mediated by elevated level of CRP, whereas the MPR is impaired in COPD through both systemic inflammation and airflow limitation.
In the current study, we used relatively long readout time per slice to obtain sufficient spatial resolution of perfusion CMR. In this setting, it is difficult to acquire three slices or more at every heartbeat except in the subject with a very low heart rate. Quantitative analysis of perfusion CMR is performed by using mainly either a deconvolution method 43 or compartment model analysis 44 in the literatures.
Jerosch-Herold et al. extensively studied a deconvolution method for the absolute quantification of MBF from first-pass myocardial perfusion CMR and found that the limited temporal resolution significantly impair the accuracy of the quantitative MBF estimates. 45 In the current study, we employed the Patlak plot technique of first-pass perfusion CMR with a temporal resolution of every two beat-to-beat intervals. The Patlak plot method is based on a two-compartment model and describes the K 1 of one-way transfer of contrast material from the blood to the myocardium. The mass balance of Gd-DTPA is described by the first-order differential equation:
where C myo (t) and C a (t) are the relative concentrations of Gd-DTPA in the myocardium and LV blood. K 1 and k 2 represent transfer constants from the blood pool to the myocardium and from the myocardium to the vascular system, respectively. In the early phase after the arrival of contrast agent in the myocardium, it is assumed that C myo (t) is negligibly small compared with C a (t). Then, the solution to Eq. (1) is:
Based on our previous study, 21 this linear relationship was confirmed to be maintained for 6-10 s before the reverse transfer of Gd-DTPA from the myocardial compartment to the vascular compartment became significant. Since the linear relationship on the Patlak plot persists for 8 s, a sufficient number of data fitting points is available for quantifying MBF in dynamic CMR images acquired every two cardiac cycles. Consequently, every two RR interval image acquisition of the first-pass myocardial perfusion CMR does not necessarily influence the accuracy of the quantitative MBF measures when the modelbased Paltak plot method is used.
Limitations
Several limitations should be acknowledged in this study. First, the present study is a single-centre, observational study and carries all of the inherent limitations of that study design. Thus, the crosssectional nature of our data does not allow one to draw conclusions as to whether COPD or systemic inflammation leads to a reduction in MPR or whether the reduced MPR causes COPD or systemic inflammation. Longitudinal studies may be able to answer this question. Secondly, it is likely that some amount of residual confounding remains despite adjustment for a wide array of clinically relevant covariates. On the other hand, compared with data derived from subjects selectively enrolled in a randomized trial, these data, with very limited exclusion criteria, may be more representative of patients seen in routine clinical practice. Thirdly, it is likely that the observed abnormalities in coronary function integrate the fluid dynamic effects of epicardial stenosis and diffuse atherosclerosis on microcirculatory function. However, the fact that 12 COPD patients who underwent coronary angiography had normal coronary arteries and the remaining 8 subjects who underwent coronary magnetic resonance angiography had non-obstructive CAD supports the notion that the impaired MPR could be related to microvascular dysfunction among those individuals. Fourthly, the use of an average extraction fraction from a separate patient cohort to convert the K 1 values into MBFs may introduce inaccuracies into the results. However, these will be constant over all the subjects, so the result obtained in the current study should not affect the conclusions of this study.
In conclusion, subjects with mild-to-moderate COPD showed decreased MPR, compared with control and control-never smokers. Altered MPR indicates an early alteration in myocardial tissue and vascular properties in these subjects with COPD. The casual detection of COPD should alert the clinician to the potential coexistence of decreased MPR. This may represent early stages of atherosclerosis and warrant the evaluation and treatment for CAD as well as assessing the risk for advancing pulmonary disease.
